debt_leverage_profile
Near-zero debt; cash-funded clinical-stage biotech with no meaningful long-term debt obligations as of 2024.
Inferred
Agent_Inference
interest_rate_sensitivity
Minimal; company holds cash/short-term investments, so rising rates marginally increase interest income, not expense.
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
API manufacturing reliance on European CMOs (Germany/Switzerland); raw material API sourcing potentially exposed to China chemical export controls.
Inferred
Agent_Inference
international_expansion_readiness
Pre-revenue clinical stage; no international commercial revenue, so sovereign currency devaluation exposure is effectively zero.
Inferred
Agent_Inference
geographic_footprint
Operations primarily US-headquartered; clinical trials run in EU/Eastern Europe; no commercial revenue currency exposure currently.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single CMO concentration risk is high; IMU-838 and IMU-935 rely on specialized contract manufacturers with limited substitutability near-term.
Inferred
Agent_Inference
business_model_type_primary
Clinical-stage biopharma; no cloud-infrastructure-dependent product; AWS/GCP termination would disrupt operations but not core drug development.
Inferred
Agent_Inference
business_model_type_secondary
Research informatics and trial data management could be disrupted; ~4–8 weeks to migrate; material but not existential risk.
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; uses standard CRO/EDC platforms (Medidata/Veeva); no proprietary API lock-in identified.
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model is pharmaceutical licensing/milestone-based, not investment-contract-like token or profit-sharing scheme.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate GDPR exposure from EU clinical trial patient data; CCPA exposure limited; requires Data Processing Agreements with EU sites.
Inferred
Agent_Inference
antitrust_exposure_flag
Negligible antitrust risk; pre-revenue niche autoimmune/oncology drug developer with no market dominance.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Currently ~0% recurring commercial revenue; 100% non-recurring grant, collaboration milestones, or equity raises.
Inferred
Agent_Inference
monetization_vector
Future monetization via pharmaceutical licensing deals, partnership milestones, and eventual drug sales upon FDA/EMA approval.
Inferred
Agent_Inference
pricing_architecture
No commercial pricing yet; future pricing likely premium specialty pharma ($50K–$150K/patient-year range for autoimmune indication).
Inferred
Agent_Inference
pricing_power_rating
Potentially high if approved; selective immunology drugs command strong pricing power with limited direct competition.
Inferred
Agent_Inference
target_gross_margin_bracket
Pharmaceutical gross margins typically 70–85% post-approval; pre-revenue stage makes current modeling speculative.
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider risk; prescription drug model with no freemium tier; future payer/reimbursement churn is the relevant risk.
Inferred
Agent_Inference
headcount_cost_structure
Sublinear growth expected post-approval; commercial launch requires salesforce build but R&D headcount growth decouples from revenue scale.
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of revenue growth post-launch is low (manufacturing COGS); primary fixed cost is R&D and regulatory overhead.
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise model.
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, physician detailing cost per prescriber declines; payer contracting becomes dominant CAC driver for specialty drug.
Inferred
Agent_Inference
network_effect_present
No network effects; drug efficacy and physician adoption are independent of user base size.
Inferred
Agent_Inference
asset_efficiency_ratio
-172.4% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate-high resilience; autoimmune diseases are chronic requiring ongoing treatment; some payer/patient cost-sensitivity risk.
Inferred
Agent_Inference
customer_segment_primary
Future: autoimmune disease patients (MS, IBD, primary sclerosing cholangitis) via physician prescription channel.
Inferred
Agent_Inference
customer_segment_secondary
Institutional: specialty pharma/biotech partners for licensing; oncology indication expanding addressable customer base.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated almost entirely to clinical-stage R&D; no legacy infrastructure reallocation; burn rate ~$40–55M/year funding trials.
Inferred
Agent_Inference
sec_cik
0001280776
High
SEC-EDGAR
ticker
IMUX
High
SEC-EDGAR